Thierry André

49PUBLICATIONS
207CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer diagnosisCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Apr 14, 2026
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

Benoist Chibaudel, Louis-Marie Dourthe, Thierry André

|Mar 26, 2026
Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Andrea Marques, Julie Henriques, Dewi Vernerey

|Jan 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

John H Strickler, Andrea Cercek, Salvatore Siena

|Dec 29, 2025
Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision-making.

Martin Duval, Antoine Dardenne, Thomas Samaille

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Oct 06, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Ming Lei, Michael J Overman, Jin Yao

Pageof 9

Frequent Collaborators

21 joint publications

Romain Cohen

14 joint publications

Julien Taieb

13 joint publications

Qian Shi

11 joint publications

Sara Lonardi